Pharma major Lupin Limited (Lupin) announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit-II) facility, India.
Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza® of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.
Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of approximately USD 10 million in the U.S. (IQVIA MAT December 2019).
Shares of LUPIN LTD. was last trading in BSE at Rs.717.85 as compared to the previous close of Rs. 703.2. The total number of shares traded during the day was 46175 in over 1661 trades.
The stock hit an intraday high of Rs. 721.35 and intraday low of 705.65. The net turnover during the day was Rs. 33053447.